Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
460
datasets available to search
ShareScore release 0.9.0
Dataset results
460 results for “SBRT;”
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
ClinicalTrials.gov study NCT06592612. IPD Sharing: YES. Countries: 0. Publications: 0.
Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516
ClinicalTrials.gov study NCT00818714. IPD Sharing: Not stated. Countries: 0. Publications: 0.
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
ClinicalTrials.gov study NCT06009029. IPD Sharing: NO. Countries: 0. Publications: 0.
HCC Response Assessment by MRI After SBRT
ClinicalTrials.gov study NCT03088423. IPD Sharing: Not stated. Countries: 0. Publications: 0.
SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases
ClinicalTrials.gov study NCT05577052. IPD Sharing: YES. Countries: 0. Publications: 0.
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
ClinicalTrials.gov study NCT06835179. IPD Sharing: NO. Countries: 0. Publications: 0.
Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT
ClinicalTrials.gov study NCT02344667. IPD Sharing: Not stated. Countries: 0. Publications: 0.
SBRT Versus Surgical Resection for Small HCC
ClinicalTrials.gov study NCT07381660. IPD Sharing: YES. Countries: 0. Publications: 0.
A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC
ClinicalTrials.gov study NCT06434740. IPD Sharing: NO. Countries: 0. Publications: 0.
MRI-guided Ultrahypofractionated SBRT Prostate Program
ClinicalTrials.gov study NCT07132658. IPD Sharing: YES. Countries: 0. Publications: 0.
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
ClinicalTrials.gov study NCT06991491. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
ClinicalTrials.gov study NCT05799443. IPD Sharing: NO. Countries: 0. Publications: 0.
To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT06154967. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib
ClinicalTrials.gov study NCT07230314. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT04255836. IPD Sharing: Not stated. Countries: 0. Publications: 0.
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
ClinicalTrials.gov study NCT06538935. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely
ClinicalTrials.gov study NCT03175146. IPD Sharing: YES. Countries: 0. Publications: 0.
SBRT in 4 Fractions for Prostate Cancer
ClinicalTrials.gov study NCT03873090. IPD Sharing: NO. Countries: 0. Publications: 0.
Dataset related to article "Phase II trial on SBRT for unresectable liver metastases long-term outcome and prognostic factors of survival after 5 years of follow-up"
<p>This record contains raw data related to article "Phase II trial on SBRT for unresectable liver metastases long-term outcome and prognostic factors of survival after 5 years of follow-up"</p> <p>BACKGROUND:</p> <p>The aim of this study was to evaluate long-term efficacy and survival prognostic factors of stereotactic body radiation therapy (SBRT) for un-resectable liver metastases in patients enrolled in a prospective phase II trial.</p> <p>METHODS AND MATERIALS:</p> <p>5-year local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates were analyzed in patients with un-resectable liver metastases enrolled in a Phase II Trial on liver SBRT, with a prescription dose of 75Gy in 3 consecutive fractions.</p> <p>RESULTS:</p> <p>A total of 61 patients with 76 lesions were enrolled, with a median follow-up time of 6.1 years. One, three and 5 year LC rates were 94 ± 3.1%, 78.0 ± 5.9% and 78.0 ± 5.9%, without reaching the median LC time. Median OS was 27.6 months and the survival rates were 85.2 ± 4.5%, 31.1 ± 5.9% and 18.0 ± 4.9% at 1, 3 and 5-year after SBRT, respectively. Univariate analysis showed that favorable primary site (colorectal, breast and gynecological) of metastases (p = 0.001) improved survival. Toxicity was moderate. One patient experienced G3 late chest wall pain, which resolved within 1 year from SBRT. No cases of Radiation Induced Liver Disease (RILD) were detected.</p> <p>CONCLUSIONS:</p> <p>Long-term results of this Phase II study suggest the efficacy and safety of SBRT for un-resectable liver metastases after 5-year of follow up. Selection of cases with positive prognostic factors may improve long-term survival of these oligo-metastastic patients and may confirm the role of SBRT as an effective alternative local therapy for liver metastases.</p>
Changes in peripheral blood mononuclear cells (PBMCs) of 10 patients who underwent continued ADT and stereotactic body radiation therapy (SBRT).
GEO Series GSE277590. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.